{
  "abstract": "Background/Objective: Once-daily INGREZZA® (valbenazine), a selective vesicular monoamine transporter 2 (VMAT2) inhibitor, is approved for tardive dyskinesia (TD) and Huntington’s chorea. KINECT-PRO™ (NCT05859698) is currently the only study to assess the effects of a VMAT2 inhibitor (valbenazine) on quality of life (QoL) and functionality in patients with TD using multiple validated patient-reported outcomes (PROs).\n\nMethods: Adults with mild-to-severe TD movement severity (per Abnormal Involuntary Movement Scale [AIMS] item 8) and awareness of TD with mild-to-severe associated distress (per AIMS item 10) received open-label valbenazine (40, 60, or 80 mg) for 24 weeks. Primary endpoints included changes from baseline (CFBs) at Week 24 in 3 validated QoL/functionality PROs: Tardive Dyskinesia Impact Scale (TDIS), the only psychometrically validated PRO developed specifically for TD; Sheehan Disability Scale (SDS); and EuroQoL Group’s EQ-Visual Analogue Scale (EQ-VAS). Secondary endpoints included CFB in AIMS total score.\n\nResults: Substantial and clinically meaningful improvements in patient-reported QoL/functionality and clinician-reported TD severity were observed throughout treatment with valbenazine in the overall study population and regardless of psychiatric diagnosis (mood disorders, psychotic disorders) or TD severity at baseline (mild, moderate/severe). At Week 24 (N = 45), mean CFBs were: TDIS (−8.0); SDS Social/Leisure (−2.3); SDS Family/Home (−1.6); EQ-VAS (+13.1); AIMS (−6.8). Previously established minimal clinically important difference (MCID) thresholds for TD were exceeded for TDIS and AIMS. Safety and tolerability were consistent with valbenazine’s known profile.\n\nConclusions: KINECT-PRO is the first study of its kind, and valbenazine is the only VMAT2 inhibitor to demonstrate QoL/functional improvements in patients with TD across multiple validated PROs.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Psychiatry Research, The Zucker Hillside Hospital, Glen Oaks, NY, USA",
    "Department of Psychiatry and Molecular Medicine, The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA",
    "Department of Child and Adolescent Psychiatry, Charité - Universitätsmedizin Berlin, Berlin, Germany",
    "German Center for Mental Health (DZPG), Partner Site Berlin, Berlin, Germany",
    "Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA",
    "Augusta University Medical College of Georgia, Augusta, GA, USA",
    "University of South Florida Morsani College of Medicine, Tampa, FL, USA",
    "University of California Riverside Medical School, Riverside, CA, USA",
    "Hoag Hospital, Newport Beach, CA, USA",
    "ATP Clinical Research, Costa Mesa, CA, USA",
    "Health Outcomes Solutions, Palm Beach Gardens, FL, USA",
    "Neurocrine Biosciences Inc., San Diego, CA, USA",
    "Neurona Therapeutics Inc., South San Francisco, USA"
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 11,
  "authors": [
    {
      "affs": [
        0,
        1,
        2,
        3
      ],
      "name": "Christoph U. Correll",
      "orcid": "0000-0002-7254-5646"
    },
    {
      "affs": [
        4
      ],
      "name": "M. Mercedes Perez-Rodriguez"
    },
    {
      "affs": [
        5
      ],
      "name": "Joseph P. McEvoy"
    },
    {
      "affs": [
        6
      ],
      "name": "David V. Sheehan"
    },
    {
      "affs": [
        7,
        8,
        9
      ],
      "name": "Gustavo Alva",
      "orcid": "0000-0001-9742-398X"
    },
    {
      "affs": [
        10
      ],
      "name": "Susan Mathias"
    },
    {
      "affs": [
        11
      ],
      "name": "Morgan Bron"
    },
    {
      "affs": [
        11
      ],
      "name": "Robert H. Farber"
    },
    {
      "affs": [
        11
      ],
      "name": "Hui Zhang"
    },
    {
      "affs": [
        12
      ],
      "name": "Eduardo Dunayevich"
    },
    {
      "affs": [
        11
      ],
      "name": "Ashok Parameswaran"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/8s9hecr8097hc.bib",
  "cited_by": 0,
  "doi": "10.1017/s1092852926101138",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13732611/",
  "id": "8s9hecr8097hc",
  "issns": [
    "1092-8529",
    "2165-6509"
  ],
  "landing_url": "https://doi.org/10.1017/s1092852926101138",
  "language": "en",
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Original Research"
    ],
    [
      "openalex",
      "2738|Schizophrenia research and treatment"
    ]
  ],
  "openalex": "W7202216319",
  "pdf_url": "https://www.cambridge.org/core/services/aop-cambridge-core/content/view/3E823471C4E877B1A58D727FE1E1D00D/S1092852926101138a.pdf/div-class-title-valbenazine-improves-quality-of-life-functionality-and-movement-severity-in-patients-with-tardive-dyskinesia-findings-from-the-kinect-pro-study-div.pdf",
  "pmcid": "PMC13732611",
  "pmid": "42576169",
  "published": "2026-08-11",
  "publisher": "Cambridge University Press",
  "ris": "https://research.draconitic.com/paper/8s9hecr8097hc.ris",
  "sources": [
    {
      "first_seen": "2026-11-08T12:22:34Z",
      "native_id": "PMC13732611",
      "source": "pmc",
      "url": "https://doi.org/10.1017/s1092852926101138"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2738|Schizophrenia research and treatment",
      "subfield": "psychiatry"
    }
  ],
  "title": "Valbenazine improves quality of life, functionality, and movement severity in patients with tardive dyskinesia: findings from the KINECT-PRO™ study",
  "title_text": "Valbenazine improves quality of life, functionality, and movement severity in patients with tardive dyskinesia: findings from the KINECT-PRO™ study",
  "type": "peer-reviewed",
  "updated_at": "2026-11-08T12:22:34Z",
  "url": "https://research.draconitic.com/paper/8s9hecr8097hc",
  "venue": "CNS Spectrums",
  "versions": []
}